News

Article

Compounding Committee Meets to Discuss Drugs Approved for Compounding

FDA’s Pharmacy Compounding Advisory Committee will meet in February to discuss the list of bulk drug substances that may or may not be compounded.

 

FDA announced on Jan. 23, 2015 that their Pharmacy Compounding Advisory Committee will meet on Feb. 23-24 to discuss the revised lists of drug substances that may not be compounded under the exemptions stated in sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. In July, FDA proposed adding 25 drug products to this list because the drug products have been withdrawn or removed from the market after the drug products or components of such drug products were found to be unsafe or not effective. The meeting will include a discussion of comments FDA received to FDA’s proposed rule on the matter in July 2014. 

The committee will also discuss six drug substances that were nominated to be included on the list of bulk drug substances approved for compounding. FDA solicited nominations for the list on Dec. 4, 2013 and July 2, 2014.

Source: FDA.gov

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content